Prexton Therapeutics raises 8.7 million euros (10 million dollars) in a Series A round


Prexton Therapeutics raises 8.7 million euros (10 million dollars) in a Series A round

Swiss based startup attracts venture funding from leading European VC firms to address Parkinson’s disease and other CNS conditions.

Geneva, Switzerland, February 24 2015 - Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including Parkinson’s disease, today announces the closing of a Series A financing of €8.7 million ($10 million) co-led by Sunstone Capital and Ysios Capital. MS Ventures, the company's founding investor, will also participate.

Download the PDF file